The global myasthenia gravis treatment market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growing adoption of rare diseases, approvals for promising drugs, increasing adoption of immunotherapies, and emergence of biologics.
Myasthenia gravis (MG) is rare, chronic, and progressive neuromuscular disorder which causes weakness of the head, eye, limb, respiratory muscles, and spinal. MG is autoimmune disorder in which against the acetylcholine receptor (AchR) antibodies are produced. Myasthenia gravis hampers the normal transmission of electrical signals from nerves to muscles.
According to the National Organization for Rare Disorders (NORD), approximately 20-35 per 100,000 individuals suffer from myasthenia gravis in the U.S. also, number of disorders are increasing over the last several decades. This is attributed to rising incidence of autoimmune disorders and better identification of patients across the globe.
Myasthenia gravis occurs generally in females than in males. Symptoms of MG appears at any age, but in men it’s appear during their 50s or 60s and in women usually in their 20s or 30s. There is no permanent cure for myasthenia gravis disease. But there are some treatments such as medications and surgery for slows down the disease progression, management of the symptoms, and prevention of unnecessary complications. Currently, researchers are majorly focused on understanding the specifics of the autoimmune problems related to MG and improving diagnosis methods and treatments. Moreover, other important area of research physiology of the neuromuscular junction (NMJ), is improving its function irrespective of probable immune system attacks.
The report on the global myasthenia gravis treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Myasthenia Gravis Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Treatments (Medication, Surgery, and Others), End-Users (Hospitals, Clinics, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc., Novartis AG, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Bausch Health Companies Inc., and Shire plc. |
Based on treatments, the myasthenia gravis treatment market is divided into medication, surgery, and others. The medication segment is expected to hold a key share of the market during the forecast period. This is due to medications are dramatically constrain the immune system and majorly manages the associated symptoms. Medications include immunotherapies such as corticosteroids, Soliris (eculizumab), and immunosuppressive drugs includes Neoral/Sandimmune (cyclosporine) and Prograf (tacrolimus).
Surgery is other major treatment alternative which includes a thymectomy (thymus removal). It is invasive in nature. The thymus deteriorates with age (thymic involution), though complete loss of the thymus in a significant manner is expected to weaken a patient’s immune system.
Increasing number of pipeline R&D of drug development is projected to fuel the growth of the myasthenia gravis treatment market. Recently, the U.S. FDA and the European Commission, approved Alexion Pharmaceuticals’ Soliris (eculizumab) for treating adult myasthenia gravis patients who are anti-AchR antibody-positive. Soliris is a complement and first inhibitor for this disorder. The rising use of immunosuppressant and monoclonal antibodies is targeted the reduction of lifelong exposure to corticosteroids.
On the basis of end-users, the myasthenia gravis treatment market is segmented into hospitals, clinics, and others. The hospital segment is expected to hold a key share of the market during the forecast period. The growth of the segment is attributed to high demand of advanced equipment for myasthenia gravis treatment and huge patient pool. Number of patient visits for the MG treatment is increasing because of accessibility of such facilities. Moreover, rising investment in state-of-the-art healthcare infrastructures is one of the major driving factor.
On the other hand, the clinic segment is anticipated to expand at a rapid pace during the forecast period. Recently, need of specialized treatments is increasing also many patients are choosing specialty clinics for effective treatment and quick diagnosis. Furthermore, many end-users are dependent on e-commerce channel for treatment. Such segments are majorly boosting the growth of myasthenia gravis treatment market.
On the basis of regions, the myasthenia gravis treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America hold largest market share and is expected to exhibit a rapid growth rate in the coming years. The regional market growth can be attributed to growing expenditure on healthcare, huge adoption of immunotherapies and monoclonal antibodies, favorable reimbursement scenario, and presence of established R&D facilities.
However, the market of Asia Pacific is anticipated to expand at an impressive CAGR during the forecast period owing to the growing generation of revenue through medications such as immunosuppressant and monoclonal antibodies in this region. Furthermore, initiatives taken by government and manufacturers for increasing investment is one of the boosting factor responsible for the regional growth.
Key players competing in the myasthenia gravis treatment market are Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc., Novartis AG, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Bausch Health Companies Inc., and Shire plc.
Many key players are launching new products and constant innovation are driving the market growth. For instance, Argenx, in June 2020, introduced its awareness efforts for autoimmune disease myasthenia gravis. Also, major market players implement several other business strategies such as mergers, acquisitions, partnerships, collaborations, and capacity expansion to enhance their market shares.
Some other reports from this category!